FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321000205> ?p ?o ?g. }

• W2321000205 abstract "Objectives To assess the effect of disease duration (≤2 y vs. >2 y) and severity (moderate [mod] vs. severe [sev]) on treatment outcomes in subjects with RA receiving ETN+MTX or DMARDs+MTX. Methods Data from subjects with mod-to-sev RA and an inadequate response to MTX were pooled from the APPEAL 1 (ETN 25 mg twice weekly+MTX or DMARD+MTX) and LatinRA 2 (ETN 50mg once weekly+MTX or DMARD+MTX) studies. 3 Endpoints included DAS28 (ESR) remission ( Results 478 subjects received ETN+MTX (≤2 y n=123, >2 y n=348; DAS28 3.2–5.1 [mod] n=45; DAS28 >5.1 [sev] n=431) and 245 subjects received DMARD+MTX (≤2 y n=60, >2 y n=180; DAS28 3.2–5.1 n=19; DAS28 >5.1 n=226). In the total population of each treatment group, ETN+MTX was more effective than DMARD+MTX (Table). Patients with ≤2 y numerically had a better response than >2 y, as did patients with mod compared with sev for both treatment groups. ETN+MTX significantly outperformed DMARD + MTX in the >2 y and sev groups in all endpoints; in the ≤2 y group only DAS28 and CDAI LDA were superior as the ≤2 y and mod group had too few patients to detect a treatment difference. Within the treatment groups, significantly higher proportions of subjects with disease duration of ≤2 y vs. >2 y achieved HAQ ≤0.5 with ETN+MTX (P Conclusions Combination ETN+MTX was more effective than DMARDs+MTX in subjects with disease duration of >2 y and sev disease activity. Achievement of remission and optimal response was generally achieved in a higher number of subjects with shorter disease duration and mod disease activity. References Kim HY et al. Int J Rheum Dis 2012;15:188-96. Machado D et al. PANLAR 2012: Poster. Fleischmann R, et al. Arthritis and Rheumatism 2012;64:S550. Acknowledgements This study was sponsored by Pfizer Inc. Medical writing support was provided by Kim Brown of UBC Scientific Solutions and was funded by Pfizer Inc. Disclosure of Interest R. Fleischmann Grant/research support from: Genentech Inc, Roche, Abbott, Amgen, UCB, Pfizer Inc, BMS, Lilly, Sanofi Aventis, Lexicon, MSD, Novartis, BiogenIdec, Astellas, Astra-Zeneca, Janssen, Consultant for: Roche, Abbott, Amgen, UCB, Pfizer, BMS, Lilly, Sanofi Aventis, Lexicon, Novartis, Astellas, Astra-Zeneca, Janssen, HGS, A. Koenig Employee of: Pfizer Inc., A. Szumski: None Declared, H. Nab Employee of: Pfizer Europe, L. Marshall Employee of: Pfizer Inc., E. Bananis Employee of: Pfizer Inc." @default.
• W2321000205 created "2016-06-24" @default.
• W2321000205 creator A5024697092 @default.
• W2321000205 creator A5041835212 @default.
• W2321000205 creator A5046261111 @default.
• W2321000205 creator A5061716516 @default.
• W2321000205 creator A5062171722 @default.
• W2321000205 creator A5090337589 @default.
• W2321000205 date "2013-06-01" @default.
• W2321000205 modified "2023-09-23" @default.
• W2321000205 title "AB0287 Efficacy of etanercept (etn) plus methotrexate (mtx) vs. disease-modifying anti-rheumatic drug (dmard) combinations with mtx in established rheumatoid arthritis (ra): duration of disease and disease severity vs. outcomes" @default.
• W2321000205 doi "https://doi.org/10.1136/annrheumdis-2013-eular.2609" @default.
• W2321000205 hasPublicationYear "2013" @default.
• W2321000205 type Work @default.
• W2321000205 sameAs 2321000205 @default.
• W2321000205 citedByCount "0" @default.
• W2321000205 crossrefType "journal-article" @default.
• W2321000205 hasAuthorship W2321000205A5024697092 @default.
• W2321000205 hasAuthorship W2321000205A5041835212 @default.
• W2321000205 hasAuthorship W2321000205A5046261111 @default.
• W2321000205 hasAuthorship W2321000205A5061716516 @default.
• W2321000205 hasAuthorship W2321000205A5062171722 @default.
• W2321000205 hasAuthorship W2321000205A5090337589 @default.
• W2321000205 hasConcept C126322002 @default.
• W2321000205 hasConcept C2777226972 @default.
• W2321000205 hasConcept C2777575956 @default.
• W2321000205 hasConcept C2781059491 @default.
• W2321000205 hasConcept C2908647359 @default.
• W2321000205 hasConcept C71924100 @default.
• W2321000205 hasConcept C90924648 @default.
• W2321000205 hasConcept C99454951 @default.
• W2321000205 hasConceptScore W2321000205C126322002 @default.
• W2321000205 hasConceptScore W2321000205C2777226972 @default.
• W2321000205 hasConceptScore W2321000205C2777575956 @default.
• W2321000205 hasConceptScore W2321000205C2781059491 @default.
• W2321000205 hasConceptScore W2321000205C2908647359 @default.
• W2321000205 hasConceptScore W2321000205C71924100 @default.
• W2321000205 hasConceptScore W2321000205C90924648 @default.
• W2321000205 hasConceptScore W2321000205C99454951 @default.
• W2321000205 hasLocation W23210002051 @default.
• W2321000205 hasOpenAccess W2321000205 @default.
• W2321000205 hasPrimaryLocation W23210002051 @default.
• W2321000205 isParatext "false" @default.
• W2321000205 isRetracted "false" @default.
• W2321000205 magId "2321000205" @default.
• W2321000205 workType "article" @default.